Mulshine, J.L. (James L.)

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations
    (Spandidos Publications, 2002) Tockman, M. (M.); Pullen, J. (J.); Lachmann, P. (P.); Herman, J. (J.); Tyndale, R. (R.); Field, J.K. (J. K.); Henschke, C.I. (C.I.); Maier, S. (S.); Youngson, J. (J.); Mulshine, J.L. (James L.); Montuenga-Badia, L.M. (Luis M.); Murphy, M. (Murphy); Caporaso, N.E. (Neil E.); Spitz, M.R. (Margaret R.); Lam, S. (S.); Wistuba, I.I. (Ignacio I.); Hirsch, F. (F.); Flahault, A. (A.); Brambilla, C. (C.)
    The Second Molecular Biomarkers Workshop was held at the Roy Castle International Centre for Lung Cancer Research in Liverpool, in June 2001 and it brought together experts in the clinical, epidemiological and molecular-pathology of lung cancer from Europe and the USA, to address issues surrounding the development of a European strategy for early lung cancer detection. The 2001 Workshop Breakout Groups concentrated on the current challenges in the early detection of lung cancer which need to be addressed in the light of the recent surge in interest in many countries for mounting new clinical trials to evaluate the utility of Spiral CT in early lung cancer detection. If population-based trials of CT screening are mounted it will also be a favorable clinical environment in which to evaluate efficiently recent advances in molecular screening and genotyping. The Workshop focused specifically on: a) clinical and molecular biomarkers, b) sputum as an early detection and diagnostic tool, c) validation of molecular markers prior to their use in early detection trials and d) ethical issues that have to be considered in early lung cancer detection trials. A distillation of the Workshop discussions is given in this article.
  • Thumbnail Image
    New molecular strategies for early lung cancer detection
    (Informa Healthcare, 2000) Mulshine, J.L. (James L.); Montuenga-Badia, L.M. (Luis M.)
  • Thumbnail Image
    Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development
    (American Thoracic Society, 1998) Zhou, J. (Jun); Adriá, Juan Antonio; Sunday, M. (Mary); Mulshine, J.L. (James L.); Montuenga-Badia, L.M. (Luis M.); Vos, M. (Michele); Cuttitta, F. (Frank); Treston, A.M. (Anthony M.); Martinez, A. (Alfredo)
    Recent reports have demostrated a link between expression of members of the family of heterogeneous nuclear ribonucleoproteins (hnRNPs) and cancer. Overexpression of hnRNP A2/B1 correlated with the eventual development of lung cancer in three different clinical cohorts. We have studied the expression of hnRNP A2/B1 messenger RNA (mRNA) and protein during mammalian development. The expression of hnRNP A2/B1 mRNA and protein are parallel but change dynamically during critical periods in mouse pulmonary development. hnRNP A2/B1 is first detected in the lung in the early pseudoglandular period, peaks at the beginning of the canalicular period, and remains high during the saccular (alveolar) period. In mouse and rat, hnRNP A2/B1 expression is first evident in the earliest lung buds. As lung development progresses, the cuboidal epithelial cells of the distal primitive alveoli show high levels of the ribonucleoprotein, which is almost undetectable in the proximal conducting airways. The expression of hnRNP A2/ B1 is restricted in mature lung. Similar dynamic pattern of expression through lung development was also found in rat and human lung. Upregulated expression of hnRNP A2/B1 at critical periods of lung development was comparable to the level of expression found in lung cancers and preneoplastic lesions and is consistent with hnRNP A2/B1 overexpression playing an oncodevelopmental role.